Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OK2004 nucleoside suppression versus continued triple therapy in virologically suppressed HIV infection
2004-001323-37Phase 4Active
- Sponsor
- Hospital Universitario 12 de Octubre
- Start
- Nov 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of lopinavir + ritonavir, lopinavir and ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Hospital Universitario 12 de Octubre. Primary endpoint: HIV RNA viral load. Started Nov 2004; status: active.
02
Drugs
lopinavir + ritonavirlopinavirritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2004-001323-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001323-37.